DE69920247D1 - Veränderung der dns methyltransferase durch kombinationstherapie - Google Patents

Veränderung der dns methyltransferase durch kombinationstherapie

Info

Publication number
DE69920247D1
DE69920247D1 DE69920247T DE69920247T DE69920247D1 DE 69920247 D1 DE69920247 D1 DE 69920247D1 DE 69920247 T DE69920247 T DE 69920247T DE 69920247 T DE69920247 T DE 69920247T DE 69920247 D1 DE69920247 D1 DE 69920247D1
Authority
DE
Germany
Prior art keywords
change
combination therapy
methyl transferase
dna methyl
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920247T
Other languages
English (en)
Other versions
DE69920247T2 (de
Inventor
M Besterman
Robert Macleod
M Siders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of DE69920247D1 publication Critical patent/DE69920247D1/de
Application granted granted Critical
Publication of DE69920247T2 publication Critical patent/DE69920247T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69920247T 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie Expired - Fee Related DE69920247T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10480498P 1998-10-19 1998-10-19
US104804P 1998-10-19
PCT/US1999/024278 WO2000023112A1 (en) 1998-10-19 1999-10-19 Modulation of gene expression by combination therapy

Publications (2)

Publication Number Publication Date
DE69920247D1 true DE69920247D1 (de) 2004-10-21
DE69920247T2 DE69920247T2 (de) 2005-09-29

Family

ID=22302488

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920247T Expired - Fee Related DE69920247T2 (de) 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie

Country Status (8)

Country Link
EP (1) EP1123111B1 (de)
JP (1) JP2002528391A (de)
AT (1) ATE275956T1 (de)
AU (1) AU766084B2 (de)
CA (1) CA2347003A1 (de)
DE (1) DE69920247T2 (de)
ES (1) ES2228119T3 (de)
WO (1) WO2000023112A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020007398A (ko) * 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
EP2093292A2 (de) * 2000-03-24 2009-08-26 Methylgene, Inc. Spezifische Hemmung von Histon-deacylasen Isoformen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB2389365A (en) * 2001-01-12 2003-12-10 Methylgene Inc Methods for specifically inhibiting histone deacetylase-4
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2446606A1 (en) * 2001-05-11 2002-11-21 Methylgene, Inc. Inhibitors of dna methyltransferase isoforms
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (de) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
DE60229890D1 (de) * 2002-09-30 2008-12-24 Hoffmann La Roche Oligonukleotide zur genotypisierung des thymidylat-synthase gens
EP1578764A4 (de) * 2002-10-21 2007-01-10 Univ New Jersey Med Thymidylatsynthasepolymorphismen zur verwendung beim screening auf krebsrisiko
JP4543188B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2699606C (en) 2007-09-17 2023-04-11 Oncomethylome Sciences Sa Novel markers for bladder cancer detection
MY163296A (en) 2011-08-30 2017-09-15 Astex Pharmaceuticals Inc Drug formulations
EP3052662B1 (de) 2013-10-01 2019-05-15 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren für genexpressionsrauschen-wirkstoffscreening und verwendungen davon
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US10519190B2 (en) 2017-08-03 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US20190374656A1 (en) * 2018-06-11 2019-12-12 Aether Therapeutics Inc. Methods for maintaining optimum dna methylation by endogenous methylation and demethylation of dna
CA3236051A1 (en) * 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5005093A (en) * 1992-10-21 1994-05-09 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Also Published As

Publication number Publication date
WO2000023112A1 (en) 2000-04-27
CA2347003A1 (en) 2000-04-27
EP1123111B1 (de) 2004-09-15
AU766084B2 (en) 2003-10-09
WO2000023112A9 (en) 2000-08-31
ES2228119T3 (es) 2005-04-01
AU6519499A (en) 2000-05-08
JP2002528391A (ja) 2002-09-03
ATE275956T1 (de) 2004-10-15
DE69920247T2 (de) 2005-09-29
EP1123111A1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
DE69920247D1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
AU2001290706A1 (en) Antisense modulation of clusterin expression
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
BR9913878A (pt) Sintases
DK1104303T3 (da) Carbohydrat eller 2 ´ -modificerede oligonukleotider med alternerende internukleosidbindinger
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
BR9810870A (pt) Regulação de expressão de quinolato fosforibosil transferase
EP1248794A4 (de) Antisens-modulierung der smad7 expression
EP1117672A4 (de) Antisense-modulation der survivin-expression
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1135402A4 (de) Antisense modulation der egr-1 expression
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
EP1189918A4 (de) Antisense-modulation der integrin-beta-3-expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
WO2003099215A3 (en) Antisense modulation of glucocorticoid receptor expression
WO2002036810A3 (en) Antisense modulation of talin expression
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee